Voltage-Gated Sodium Channel Blockers
"Voltage-Gated Sodium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
| Descriptor ID |
D061567
|
| MeSH Number(s) |
D27.505.519.562.750.500 D27.505.954.411.720.500
|
| Concept/Terms |
Voltage-Gated Sodium Channel Blockers- Voltage-Gated Sodium Channel Blockers
- Voltage Gated Sodium Channel Blockers
- Voltage-Gated Sodium Channel Inhibitors
- Voltage Gated Sodium Channel Inhibitors
- Channel Blockers, Voltage-Gated Sodium
- Channel Blockers, Voltage Gated Sodium
- Voltage-Gated Sodium Channel Antagonists
- Voltage Gated Sodium Channel Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Voltage-Gated Sodium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Voltage-Gated Sodium Channel Blockers".
This graph shows the total number of publications written about "Voltage-Gated Sodium Channel Blockers" by people in this website by year, and whether "Voltage-Gated Sodium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Voltage-Gated Sodium Channel Blockers" by people in Profiles.
-
In silico drug repurposing in COVID-19: A network-based analysis. Biomed Pharmacother. 2021 Oct; 142:111954.
-
Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Feb 11; 22(1):131.
-
Successful long-term therapy with flecainide in a family with paramyotonia congenita. J Neurol Neurosurg Psychiatry. 2018 11; 89(11):1232-1234.
-
Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav. 2018 03; 80:365-369.
-
Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity. Heart Rhythm. 2017 10; 14(10):1442-1448.